Myelodysplastic syndrome in an alemtuzumab-treated multiple sclerosis patient

被引：2
|
作者：
Kim, Jean Hee [1 ]
Park, Silvia [2 ]
Kim, Woojun [1 ]
机构：
[1] Catholic Univ Korea, Seoul St Marys Hosp, Dept Neurol, Coll Med, 222 Banpo daero, Seoul, South Korea
[2] Catholic Univ Korea, Seoul St Marys Hosp, Dept Hematol, Coll Med, 222 Banpo daero, Seoul, South Korea
来源：
NEUROLOGICAL SCIENCES | 2022年 / 43卷 / 09期
关键词：
D O I：
10.1007/s10072-022-06124-6
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：5651 / 5653
页数：3
相关论文
共 50 条
  • [1] Myelodysplastic syndrome in an alemtuzumab-treated multiple sclerosis patient
    Jean Hee Kim
    Silvia Park
    Woojun Kim
    Neurological Sciences, 2022, 43 : 5651 - 5653
  • [2] Case Report: Adult Still's Disease in an Alemtuzumab-Treated Multiple Sclerosis Patient
    Kraemer, Julia
    Kroemer-Olbrisch, Tanja
    Lakomek, Heinz-Juergen
    Schellinger, Peter D.
    Foell, Dirk
    Meuth, Sven G.
    Straeten, Vera
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [3] A descriptive analysis of infectious adverse events in alemtuzumab-treated multiple sclerosis patients
    Wray, S.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S247 - S247
  • [4] Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management
    Decallonne, Brigitte
    Bartholome, Emmanuel
    Delvaux, Valerie
    D'haeseleer, Miguel
    El Sankari, Souraya
    Seeldrayers, Pierrette
    Van Wijmeersch, Bart
    Daumerie, Chantal
    ACTA NEUROLOGICA BELGICA, 2018, 118 (02) : 153 - 159
  • [5] IgG4-related autoimmune manifestations in Alemtuzumab-treated multiple sclerosis patients
    Vakrakou, Aigli G.
    Tzanetakos, Dimitrios
    Evangelopoulos, Maria-Eleptheria
    Fragoulis, George E.
    Kazakou, Paraskevi
    Lekka, Eleni
    Kafasi, Nikolitsa
    Tzartos, John S.
    Andreadou, Elissavet
    Koutsis, Georgios
    Gialafos, Elias
    Dimitrakopoulos, Antonios
    Zampeli, Evanthia
    Rontogianni, Dimitra
    Theocharis, Stamatios
    Zapanti, Evangelia
    Stathopoulos, Panos-Alexis
    Anagnostouli, Maria
    Stefanis, Leonidas
    Kilidireas, Constantinos
    JOURNAL OF NEUROIMMUNOLOGY, 2021, 361
  • [6] Detection of thyroid malignancies in alemtuzumab-treated patients in the multiple sclerosis clinical development program
    Lecumberri, B.
    Arnold, D. L.
    Cohen, J. A.
    Coles, A. J.
    Fox, E. J.
    Hartung, H-P.
    Havrdova, E.
    Selmaj, K. W.
    Margolin, D. H.
    Kasten, L.
    Panzara, M. A.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 579 - 580
  • [7] Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management
    Brigitte Decallonne
    Emmanuel Bartholomé
    Valérie Delvaux
    Miguel D’haeseleer
    Souraya El Sankari
    Pierrette Seeldrayers
    Bart Van Wijmeersch
    Chantal Daumerie
    Acta Neurologica Belgica, 2018, 118 : 153 - 159
  • [8] Detection and management of immune thrombocytopenia in alemtuzumab-treated patients in the multiple sclerosis clinical development program
    Cuker, A.
    Arnold, D. L.
    Cohen, J. A.
    Coles, A. J.
    Fox, E. J.
    Hartung, H. -P.
    Havrdova, E.
    Selmaj, K. W.
    Margolin, D. H.
    Kasten, L.
    Panzara, M. A.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 279 - 280
  • [9] Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis
    Akguen, Katja
    Blankenburg, Judith
    Marggraf, Michaela
    Haase, Rocco
    Ziemssen, Tjalf
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [10] Persistent total suppression of T follicular regulatory lymphocytes in alemtuzumab-treated multiple sclerosis patients
    Puthenparampil, M.
    Grassivaro, F.
    Rinaldi, F.
    Perini, P.
    Federle, L.
    Quaggia, E.
    Pantano, G.
    Plebani, M.
    Gallo, P.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 933 - 934
12345